Mark G. Kris, MD

News

A New ADC for Lung Cancer: Datopotamab Deruxtecan Now Approved by FDA

Author:: Mark G. Kris, MD

Publish date: August 19, 2025

Approval brings additional challenges in terms of adverse affects, but they are manageable.

Opinion

‘We Need to Rethink Our Options’: Lung Cancer Recurrence

Author:: Mark G. Kris, MD

Publish date: April 25, 2024

“Suddenly, we have better tools to control systemic spread.”

News

Unlikely Breakthrough of the Year: Chemo for Lung Cancer

Author:: Mark G. Kris, MD

Publish date: February 1, 2024

Dr. Mark Kris discusses the importance of chemotherapy in lung cancer treatment.

Opinion

How to think about second-line therapy in NSCLC

Author:: Mark G. Kris, MD

Publish date: November 2, 2023

We really have to do better.

Opinion

Neoadjuvant advantages: Treating locally advanced lung cancer

Author:: Mark G. Kris, MD

Publish date: October 18, 2023

I think that it’s time to change some of our standards. When patients appear with lung cancers other than tiny ones that might be detected through ...

Opinion

New ‘C word’: Cure should be the goal for patients with lung cancer

Author:: Mark G. Kris, MD

Publish date: September 20, 2023

I didn’t hear it at ASCO, but the truth of the matter is that’s a word we should be using and be using more.

Opinion

Standard-of-care therapy in lung cancer: Be open to new ideas

Author:: Mark G. Kris, MD

Publish date: March 15, 2023

There’s no doubt that our outcomes are better for patients, but it’s much harder to make the best choice and I think there’s more pressure on us to...

Opinion

Postop RT: Meaningful survival improvement in N2 lung cancer

Author:: Mark G. Kris, MD

Publish date: February 24, 2023

“When you have patients with N2 disease, after the completion of systemic therapies, think about the use of PORT and get the advice of a radiation ...

Opinion

ctDNA shows promise for assessing lung cancer treatment response

Author:: Mark G. Kris, MD

Publish date: February 14, 2022

These are critical therapies because they are given with the intention of improving the chance for cure.

Opinion

Alleviating chemo-related nausea is a huge unmet need

Author:: Mark G. Kris, MD

Publish date: February 3, 2022

We control nausea in only half of the patients who receive cisplatin in 2022. That is a huge issue.

Article

Highlights in Non–Small Cell Lung Cancer From ASCO 2020

Author:: Mark G. Kris, MD

Publish date: June 22, 2020

Dr. Mark Kris reports on key studies in NSCLC from ASCO 2020, including the pra...